

Classes of medications reported by patients

Class of Medications	Number of respondents (%)
<p style="text-align: center;">Antihypertensive medication</p> <p>Selective and Non-Selective Beta-Blockers: 7/65 (10.8%) Angiotensin Converting Enzyme (ACE) Inhibitors: 15/65 (23.1%) Angiotensin II Receptor Blockers: 10/65 (15.4%) Calcium-Channel Blockers: 15/65 (23.1%) Diuretics: 14/65 (21.5%)</p>	65/240 (27.1%)
<p style="text-align: center;">Hypolipidemic medication</p> <p>HMG CoA Reductase Inhibitors (Statins): 37/42 (88.1%)</p>	42/240 (17.5%)
<p style="text-align: center;">Dietary supplements</p>	38/240 (15.8%)
<p style="text-align: center;">Psychiatric medications</p> <p>Selective Serotonin Reuptake Inhibitors: 11/33 (33.3%) Tricyclic Antidepressants: 2/33 (6.0%)</p>	33/240 (13.8%)
<p style="text-align: center;">Blood thinners</p> <p>Anticoagulants: 4/30 (1.3%) Antiplatelets: 26/30 (86.7%)</p>	30/240 (12.5%)
<p style="text-align: center;">Analgesic medication</p> <p>Non-Steroidal Antiinflammatory Drugs (NSAIDs): 19/21 (90.5%) Opioids: 2/21 (9.5%)</p>	27/240 (11.3%)
<p style="text-align: center;">Hypoglycemic medications</p> <p>Type I Diabetes Medication (insulin): 7/23 (30.4%) Type II Diabetes Medication: 16/23 (69.6%)</p>	23/240 (9.6%)

COPD and asthma medication	21/240 (8.8%)
Hypothyroid medication	20/240 (8.3%)
Oral contraceptive medication	14/240 (5.9%)
Gastric ulcer medication Proton Pump Inhibitors: 10/13 (76.9%) Histamine Blockers: 3/13 (23.1%)	13/240 (5.4%)
Antibiotic medication	9/240 (3.8%)
Hormone replacement therapy (Estrogen and/or progesterone)	7/240 (2.9%)
Corticosteroid medication	6/240 (2.5%)
Oral sedatives	5/240 (2.1%)
Anticonvulsant medication	4/240 (1.7%)
Immunosuppressant medication	4/240 (1.7%)
Bisphosphonate medication Oral bisphosphonates: 3/3 (100%) IV bisphosphonates: 0/3 (0%)	3/240 (1.3%)
Benign prostatic hypertrophy medication	3/240 (1.3%)
Antihistamine medication	3/240 (1.3%)

Ophthalmic medication	3/240 (1.3%)
Antimigraine agents	3/240 (1.3%)
Anticholinergic medications	2/240 (0.8%)
Antiparkinson agents	2/240 (0.8%)
Fertility treatment	1/240 (0.4%)